x99 casino
Can Dhaka’s spirit be reclaimed?By COLLEEN SLEVIN DENVER (AP) — Amid renewed interest in the killing of JonBenet Ramsey triggered in part by a new Netflix documentary, police in Boulder, Colorado, refuted assertions this week that there is viable evidence and leads about the 1996 killing of the 6-year-old girl that they are not pursuing. JonBenet Ramsey, who competed in beauty pageants, was found dead in the basement of her family’s home in the college town of Boulder the day after Christmas in 1996. Her body was found several hours after her mother called 911 to say her daughter was missing and a ransom note had been left behind. The details of the crime and video footage of JonBenet competing in pageants propelled the case into one of the highest-profile mysteries in the United States. The police comments came as part of their annual update on the investigation, a month before the 28th anniversary of JonBenet’s killing. Police said they released it a little earlier due to the increased attention on the case, apparently referring to the three-part Netflix series “Cold Case: Who Killed JonBenet Ramsey.” In a video statement, Boulder Police Chief Steve Redfearn said the department welcomes news coverage and documentaries about the killing of JonBenet, who would have been 34 this year, as a way to generate possible new leads. He said the department is committed to solving the case but needs to be careful about what it shares about the investigation to protect a possible future prosecution. “What I can tell you though, is we have thoroughly investigated multiple people as suspects throughout the years and we continue to be open-minded about what occurred as we investigate the tips that come into detectives,” he said. The Netflix documentary focuses on the mistakes made by police and the “media circus” surrounding the case. JonBenet was bludgeoned and strangled. Her death was ruled a homicide, but nobody was ever prosecuted. Police were widely criticized for mishandling the early investigation into her death amid speculation that her family was responsible. However, a prosecutor cleared her parents, John and Patsy Ramsey, and brother Burke in 2008 based on new DNA evidence from JonBenet’s clothing that pointed to the involvement of an “unexplained third party” in her slaying. The announcement by former district attorney Mary Lacy came two years after Patsy Ramsey died of cancer. Lacy called the Ramseys “victims of this crime.” Related Articles National News | Northern lights may be faintly visible across parts of the US this Thanksgiving National News | Trump transition says Cabinet picks, appointees were targeted by bomb threats, swatting attacks National News | White House pressing Ukraine to draft 18-year-olds so they have enough troops to battle Russia National News | Trump vows tariffs over immigration. What the numbers say about border crossings, drugs and crime National News | Travelers who waited to make Thanksgiving trips are hitting the biggest crowds so far John Ramsey has continued to speak out for the case to be solved. In 2022, he supported an online petition asking Colorado’s governor to intervene in the investigation by putting an outside agency in charge of DNA testing in the case. In the Netflix documentary, he said he has been advocating for several items that have not been prepared for DNA testing to be tested and for other items to be retested. He said the results should be put through a genealogy database. In recent years, investigators have identified suspects in unsolved cases by comparing DNA profiles from crime scenes and to DNA testing results shared online by people researching their family trees. In 2021, police said in their annual update that DNA hadn’t been ruled out to help solve the case, and in 2022 noted that some evidence could be “consumed” if DNA testing is done on it. Last year, police said they convened a panel of outside experts to review the investigation to give recommendations and determine if updated technologies or forensic testing might produce new leads. In the latest update, Redfearn said that review had ended but that police continue to work through and evaluate a “lengthy list of recommendations” from the panel. Amy Beth Hanson contributed to this report from Helena, Montana.
Soccer-Dominant Liverpool beat Real Madrid 2-0 to top Champions League
The AP Top 25 women’s college basketball poll is back every week throughout the season! Get the poll delivered straight to your inbox with AP Top 25 Poll Alerts. Sign up here . HENDERSON, Nev. (AP) — Ashlon Jackson scored a career-high 30 points and No. 13 Duke defeated No. 9 Kansas State, 73-62 on Monday, in the semifinals of the Ball Dawgs Classic. The Blue Devils (6-1) overcame an early 11-point deficit behind Jackson’s shooting to advance to Wednesday’s championship game against No. 8 Oklahoma, an 85-62 winner against DePaul. Jackson, who has scored in double figures in all six of Duke’s games, shot 12 of 19 (63.1%) from the floor, including 6 of 9 (66.7%) from 3-point range. Reigan Richardson added 16 points for the Blue Devils. Kansas State (5-1) was led by Ayoka Lee, who had 16 points. Serena Sundell scored 15 and Kennedy Taylor came off the bench to add 11 for the Wildcats. Takeaways Kansas State: With her 16-point performance, Lee needs 48 points to pass Kendra Wecker (2001-05) for the Kansas State career scoring record. Wecker scored 2,333 points. Lee, the 2024-25 Preseason Big 12 Player of the Year, is averaging 15.3 points. Duke: Jackson hit her season average of 13.3 points by the 3:54 mark of the second quarter when her pull-up jumper gave her 14. The junior guard was 8 of 11 from the floor, including 4 of 5 from 3-point range, and had 20 points by halftime. RELATED COVERAGE K-State out to snap 2-game skid as Cincinnati comes to town trying to reach bowl eligibility Arizona State holds on to beat No. 20 Kansas State 24-14 and remain in the Big 12 title picture LSU beats Kansas State 76-65 behind Cam Carter’s 20 points against his former team Key moment With the Blue Devils trailing by six midway through the second quarter, Jackson triggered a 15-0 run with 13 of the team’s points to help Duke take a lead they’d never relinquish. Up next Duke will face No. 8 Oklahoma on Wednesday in the championship game, while Kansas State will face DePaul in the consolation game. ___ Get poll alerts and updates on AP Top 25 basketball throughout the season. Sign up here. AP women’s college basketball: https://apnews.com/hub/ap-top-25-womens-college-basketball-poll and https://apnews.com/hub/womens-college-basketball
Police deny sitting on evidence as Netflix doc brings renewed attention to JonBenet Ramsey’s killingAustralia coach Joe Schmidt looks set to be boosted by the availability of rugby league convert Joseph-Aukuso Sua'ali'i for Saturday's eagerly anticipated clash with Ireland. Sua'ali'i made a big impression on his Wallabies debut against England, but hurt his wrist in Sunday's defeat to Scotland. According to the Sydney Morning Herald, the athletically gifted centre did not do any structural damage when tackling Sione Tuipulotu and could be fit to face Ireland. One man who won't be at the Aviva Stadium is La Rochelle power house Will Skelton who has returned to France because Saturday's game falls outside World Rugby's release window. Second row Jeremy Williams is available after illness ruled him out of the Scotland game.
Researchers from a local university are conducting a community-led research project to map the drug crisis in Surrey. Michael Ma, PhD and Tara Lyons, PhD from Kwantlen Polytechnic University (KPU) are working with the Surrey Union of Drug Users (SUDU) to highlight "the lack of specific research on Surrey’s toxic drug supply crisis, harm reduction and the regulation of people who use drugs," notes a KPU news release Tuesday (Dec. 10). Surrey had the second-highest number of drug overdose deaths in the province for the first nine months of 2024, according to the . Gina Egilson, a board member at SUDU, said, "Surrey's losing more and more people to toxic drug overdoses, with at least four to five people dying every week." “There's a deep urgency to improve the system through more support and resources in Surrey. This research will be an empowering skill-building opportunity that will help guide SUDU's advocacy." In an , Ma noted that the majority of research on overdoses in B.C. is focused on Vancouver's Downtown Eastside, even though most overdoses have occurred in Vancouver, Surrey and Victoria. “For too many years there hasn't been enough focus on the escalating drug crisis in Surrey,” Ma said. “So we want to try to build more capacity and support in Surrey through resources, funding and infrastructure.” The project will draw from people with lived experience of substance use, who will take an "active role as participants and collaborators in the research," notes the KPU release. “This research is just not for pure scholarly academic reasons. It’s a community development project that has a research component. It can be leveraged for social action to generate new social, economic and political policy that could benefit people who are suffering, being misunderstood or being under-researched,” Ma said. Pete Woodrow, a board member at SUDU, said, “I've never seen this kind of collaboration between people of lived experience and established researchers." “It not only creates a bridge of understanding between two groups that would not normally have contact, it also gives us an opportunity to gain a greater handle on where services are most needed. So often the intent of help falls short or misses the mark due to the lack of a proper map of marginalized population.” Lyons added, “We don’t see people as objects of study in the work we're doing. They're experts who are guiding the kind of questions we're going to ask and how we will communicate the information.” A $339,159 grant from the will help fund this project.GCC tackles regional threats
Major poll puts Ireland’s lead parties near neck-and-neckFresh off their open date, the Baltimore Ravens prepare for their schedule to become busyMIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. NSPR , developer of the CGuardTM Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott ABT in April 2023. Paul Stuka, Chairman of the Board of InspireMD, stated, "We are extremely fortunate to add Scott to what I consider to be a world-class Board of Directors. With his extensive operational experience and track record in the cardiovascular space, his insights will be invaluable as the Company rapidly approaches potential U.S. approval of CGuard Prime, the most significant value inflection point in its history. I look forward to Scott's contributions and believe he will have an immediate impact." Marvin Slosman, Chief Executive Officer of InspireMD and Board member, commented, "The addition of Scott to our Board adds tremendous experience in the cardiovascular field, with a track record of growth and innovation as an executive, a board member and investor. His experience and legacy in the space will help guide us through our next stages of advancing our novel carotid platform as part of a comprehensive approach to catalyzing on the market shift toward a stent first standard while also guiding our pipeline of innovation, including our CAS, TCAR and Neuro focus." "I am very excited to join the InspireMD Board at such a transformational time for the company," added Mr. Ward. "With an impressive body of data demonstrating the superior short- and long-term patient outcomes of its novel CGuard Prime carotid stent system, I believe that CGuard, when approved in the U.S., will quickly become a new standard-of-care for carotid intervention and stroke prevention. I look forward to working with my fellow Board members and the InspireMD leadership team to achieve this goal." Mr. Ward has over 40 years of experience in the healthcare industry, including nearly 30 years at Medtronic, Inc. where he served in various leadership roles including as Senior Vice President and President of the CardioVascular, Neurological and Diabetes businesses. Mr. Ward is the Founder of Raymond Holdings, a firm with activities in venture capital, strategy and transactional advisory services for medical technology and life science companies. He earned his Bachelor of Science in Genetics and Cell Biology, his Master of Science in Toxicology, and his Master of Business Administration, all from the University of Minnesota. About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet ® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD's common stock is quoted on the Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com . Forward-looking Statements This press release contains "forward-looking statements." Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team's expectations, hopes, beliefs, intentions or strategies regarding the future. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential", "scheduled" or similar words. Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team's or directors' expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation, including potential U.S. commercial launch.. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company's control, and cannot be predicted or quantified and consequently; actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with our history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives, and substantial doubt regarding our ability to continue as a going concern; our need to raise additional capital to meet our business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute our stockholders' ownership interests; market acceptance of our products; an inability to secure and maintain regulatory approvals for the sale of our products; negative clinical trial results or lengthy product delays in key markets; our ability to maintain compliance with the Nasdaq listing standards; our ability to generate revenues from our products and obtain and maintain regulatory approvals for our products; our ability to adequately protect our intellectual property; our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology is an attractive alternative to other procedures and products; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; entry of new competitors and products and potential technological obsolescence of our products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with our research and products and potential product liability claims; product malfunctions; price increases for supplies and components; insufficient or inadequate reimbursement by governmental and other third-party payers for our products; our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; the escalation of hostilities in Israel, which could impair our ability to manufacture our products; and current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov . The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. Investor Contacts: Craig Shore Chief Financial Officer InspireMD, Inc. 888-776-6804 craigs@inspiremd.com Chuck Padala, Managing Director LifeSci Advisors 646-627-8390 chuck@lifesciadvisors.com investor-relations@inspiremd.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Globus Medical stock soars to all-time high of $84.89MyElectricsparks making waves in Pakistan with valuable tech insights